Long-term safety and effectiveness of etanercept in JIA: an 18-year experience from the BiKeR registry

BACKGROUND: At present, etanercept represents the most commonly prescribed biologic agent for juvenile idiopathic arthritis (JIA) treatment. Children and adolescents with JIA are often treated with etanercept over long periods, sometimes even into adulthood. The objectives of this analysis were to d...

Descripción completa

Detalles Bibliográficos
Autores principales: Armaroli, Giulia, Klein, Ariane, Ganser, Gerd, Ruehlmann, Michael J., Dressler, Frank, Hospach, Anton, Minden, Kirsten, Trauzeddel, Ralf, Foeldvari, Ivan, Kuemmerle-Deschner, Jasmin, Weller-Heinemann, Frank, Urban, Andreas, Horneff, Gerd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7597050/
https://www.ncbi.nlm.nih.gov/pubmed/33121528
http://dx.doi.org/10.1186/s13075-020-02326-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7597050/
https://www.ncbi.nlm.nih.gov/pubmed/33121528
http://dx.doi.org/10.1186/s13075-020-02326-5

Ejemplares similares